May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Low Fluence Photodynamic Therapy in Chronic Central Serous Chorioretinopathy: Blind Randomised Clinical Trial of Efficacy and Safety
Author Affiliations & Notes
  • F. Boscia
    Dept of Ophthalmology, University of Bari, Bari, Italy
  • M. Reibaldi
    Dept of Ophthalmology, University of Catania, Catania, Italy
  • A. Longo
    Dept of Ophthalmology, University of Catania, Catania, Italy
  • S. Faro
    Dept of Ophthalmology, University of Catania, Catania, Italy
  • M. Uva
    Dept of Ophthalmology, University of Catania, Catania, Italy
  • N. Cardascia
    Dept of Ophthalmology, University of Bari, Bari, Italy
  • A. Russo
    Dept of Ophthalmology, University of Catania, Catania, Italy
  • M. Sanfilippo
    Dept of Ophthalmology, University of Catania, Catania, Italy
  • G. Sborgia
    Dept of Ophthalmology, University of Bari, Bari, Italy
  • C. Furino
    Dept of Ophthalmology, University of Bari, Bari, Italy
  • Footnotes
    Commercial Relationships  F. Boscia, None; M. Reibaldi, None; A. Longo, None; S. Faro, None; M. Uva, None; N. Cardascia, None; A. Russo, None; M. Sanfilippo, None; G. Sborgia, None; C. Furino, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 3278. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      F. Boscia, M. Reibaldi, A. Longo, S. Faro, M. Uva, N. Cardascia, A. Russo, M. Sanfilippo, G. Sborgia, C. Furino; Low Fluence Photodynamic Therapy in Chronic Central Serous Chorioretinopathy: Blind Randomised Clinical Trial of Efficacy and Safety. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3278. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate in a blind randomized clinical trial the efficacy and safety profile of photodinamic therapy (PDT) with a low fluence rate for treatment of chronic central serous chorioretinopathy (CSC) compared to an untrated group.

Methods: : Sixteen eyes with chronic CSC were randomized into 2 groups to receive either PDT with verteporfin (fluence 25 J/cm2, light dose rate: 300 mW/cm2) or no therapy. Inclusion criteria were: Best-corrected visual acuity (BCVA) between 0,2 and 1 logMAR; presence of subretinal fluid and/or serous pigment epithelial detachment on optical coherence tomography (OCT) without regression for 3 or more months, RPE leakage on fluorescein angiography and choroidal vascular hyperpermeability on confocal scanning laser indocyanine green angiography (SLO-ICGA). Exclusion criteria were: any previous treatment for CSC; evidence of other chorioretinal disorders; media opacities; and treatment with systemic steroids. The laser irradiation was applied on the areas of choroidal vascular hyperpermeability as observed on ICGA. Nonconfluent laser spots were used in case of multiple hyperpermeable areas, including the fovea, if involved. Primary outcome measures were: far BCVA (logMAR, using ETDRS charts) and near BCVA (logMAR, using MNRead Acuity Charts), central macular thickness (OCT3, Zeiss-Humphrey); secondary outcome measures were macular sensitivity and stability of fixation determined using microperimetry (Nidek MP1). All outcome measures were evaluated 1, 4, 12 and 24 weeks after treatment.

Results: : No significant changes in all parameters were seen in control untreated group. A significant improvement of far and near BCVA were seen in comparison with both baseline (ANOVA, p=0,008 and 0,000), and the control group (t-TEST, p=0,010 and p=0,000), with the greater effect on week 24. In all eyes treated with low fluence PDT a complete resolution of subretinal fluid was observed, with a significant reduction of central macular thickness. On week 24, in treated eyes a significant improvement in mean fixation stability was also observed (ANOVA, p=0,011). No recurrence was seen during the follow-up period. No adverse event, like persistent occlusive effect on the choriocapillaris, pigmentary changes in the treatment zone, or choroidal neovascularization occurred in any of the treated patients.

Conclusions: : Low fluence PDT is effective and safe for treating chronic CSC.

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • photodynamic therapy • retinal pigment epithelium 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×